The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated ...

The FDA accepted a supplemental new drug application to darolutamide plus androgen deprivation therapy for metastatic hormone ...

The FDA granted a fast track designation to ALE-P02 for patients with CLDN1-positive squamous solid tumors. The FDA granted ...

Clinicians should consider a rapid taper approach for patients with cancer who exhibit repeated signs of opioid misuse, an ...

While bispecific antibodies tend to be well-tolerated for patients with multiple myeloma, there are still adverse effects clinicians should discuss with their patients. The use of bispecific ...

Mirdametinib led to confirmed responses and meaningful pain and health-related quality of life improvements in both children and adults with neurofibromatosis type 1-associated PNs.

The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with ...

Real-world results may differ from those seen in clinical trials for CAR T-cell therapy and bispecific antibodies for the ...

At a recent Community Case Forum, an expert discussed the risk of cytokine release syndrome after patients undergo CAR T-cell therapy. When treating patients with myeloma with CAR T-cell therapy, it ...

Topical treatments may help ease chemotherapy-induced peripheral neuropathy, but more research is needed. Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect for patients ...